Anti-LYVE1 antibody (ab10278)
Key features and details
- Rabbit polyclonal to LYVE1
- Suitable for: IHC-Fr, Flow Cyt, IHC-P, WB
- Reacts with: Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-LYVE1 antibody
See all LYVE1 primary antibodies -
Description
Rabbit polyclonal to LYVE1 -
Host species
Rabbit -
Tested applications
Suitable for: IHC-Fr, Flow Cyt, IHC-P, WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Rat -
Immunogen
-
Positive control
- human colon carcinoma
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
Constituent: PBS -
Concentration information loading...
-
Purity
Protein A purified -
Purification notes
Protein-A Chromatography (+his tag depleted). -
Primary antibody notes
The lymphatic vasculature forms a second circulatory system that drains extracellular fluid from the tissues and provides an exclusive environment in which immune cells can encounter and respond to foreign antigen. Recently a number of interesting molecules have been identified that may be exploited as markers for lymphatic endothelium, including the hyaluronan receptor LYVE1, PALE, VEGFR3, podoplanin. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab10278 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-Fr | (1) |
Use a concentration of 6 - 30 µg/ml.
Fix sections for 10 min at -20°C in MeOH. |
Flow Cyt | (1) |
Use at an assay dependent concentration.
|
IHC-P | (2) |
Use a concentration of 2 µg/ml.
|
WB |
Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 35-45 kDa (predicted molecular weight: 35 kDa).
|
Notes |
---|
IHC-Fr
Use a concentration of 6 - 30 µg/ml. Fix sections for 10 min at -20°C in MeOH. |
Flow Cyt
Use at an assay dependent concentration. |
IHC-P
Use a concentration of 2 µg/ml. |
WB
Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 35-45 kDa (predicted molecular weight: 35 kDa). |
Target
-
Function
Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes. -
Tissue specificity
Mainly expressed in endothelial cells lining lymphatic vessels. -
Sequence similarities
Contains 1 Link domain. -
Post-translational
modificationsO-glycosylated. -
Cellular localization
Membrane. Localized to the plasma membrane and in vesicles near extranuclear membranes which may represent trans-Golgi network (TGN) and endosomes/prelysosomeal compartments. Undergoes ligand-dependent internalization and recycling at the cell surface. - Information by UniProt
-
Database links
- Entrez Gene: 10894 Human
- Entrez Gene: 293186 Rat
- Omim: 605702 Human
- SwissProt: Q9Y5Y7 Human
- Unigene: 655332 Human
-
Alternative names
- Cell surface retention sequence-binding protein 1 antibody
- CRSBP 1 antibody
- CRSBP-1 antibody
see all
Images
-
Immunohistochemistry (Frozen sections) analysis of human colon carcinoma tissue sections labelling LYVE1 with ab10278.
-
ab10278 (2µg/ml) staining LYVE1 in human colon using an automated system (DAKO Autostainer Plus). Using this protocol there is lymphatic endothelium staining of lymphatic ducts where blood vessel endothelium and smooth muscle is wholly negative.
Sections were rehydrated and antigen retrieved with the Dako 3-in-1 AR buffer citrate pH 6.0 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required. -
All lanes : Anti-LYVE1 antibody (ab10278) at 1 µg/ml
Lane 1 : A549 (Human lung adenocarcinoma epithelial cell line) Whole Cell Lysate
Lane 2 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 35 kDa
Observed band size: 37 kDa why is the actual band size different from the predicted?
Additional bands at: 22 kDa, 55 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 4 minutes
LYVE-1 contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted. -
Flow Cytometry analysis of human dermal microvascular endothelial cells (HDMVEC) labelling LYVE1 with ab10278.
-
Rat skin was fixed with paraformaldehyde in 15% saturated picric acid solution for 4hr. Prior to sectioning, the specimen was infiltrated in O.C.T. and frozen in isopentane. The frozen specimen was sectioned these were rinsed in PBS for 15 min to remove O.C.T. and incubated in a 3% sodium deoxycholate solution. The specimens were rinsed twice with distilled water and then with PBS three times. The sections were incubated in 10% normal goat serum for 12 hr at 4°C, then for 12 hr with ab10278. After washing with PBS, the specimens were incubated with Alexa Fluor® 555-conjugated goat anti-rabbit IgG (H+L) (1:500), for 12 hr at 4°C. The cell nuclei were counterstained with YoYo-1. Images were obtained by using confocal microscope.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (13)
ab10278 has been referenced in 13 publications.
- Michalak-Micka K et al. Expression Profile of CD157 Reveals Functional Heterogeneity of Capillaries in Human Dermal Skin. Biomedicines 10:N/A (2022). PubMed: 35327478
- Pontiggia L et al. Bioprinting and plastic compression of large pigmented and vascularized human dermo-epidermal skin substitutes by means of a new robotic platform. J Tissue Eng 13:20417314221088513 (2022). PubMed: 35495096
- Li J et al. ZKSCAN5 Activates VEGFC Expression by Recruiting SETD7 to Promote the Lymphangiogenesis, Tumour Growth, and Metastasis of Breast Cancer. Front Oncol 12:875033 (2022). PubMed: 35600335
- Wu S et al. A Dual Targeting Magnetic Nanoparticle for Human Cancer Detection. Nanoscale Res Lett 14:228 (2019). PubMed: 31289961
- Li P et al. Clinical significance of CCBE1 expression in lung cancer. Mol Med Rep 17:2107-2112 (2018). PubMed: 29207117